These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9443475)

  • 1. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease.
    Tapiola T; Lehtovirta M; Ramberg J; Helisalmi S; Linnaranta K; Riekkinen P; Soininen H
    Neurology; 1998 Jan; 50(1):169-74. PubMed ID: 9443475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau protein in cerebrospinal fluid from semantic dementia patients.
    Andersen C; Froelich Fabre S; Ostberg P; Lannfelt L; Wahlund L
    Neurosci Lett; 2000 Nov; 294(3):155-8. PubMed ID: 11072138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
    Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
    Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
    Arai H; Higuchi S; Sasaki H
    Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.
    Skoog I; Vanmechelen E; Andreasson LA; Palmertz B; Davidsson P; Hesse C; Blennow K
    Neurodegeneration; 1995 Dec; 4(4):433-42. PubMed ID: 8846237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.
    Andreasen N; Minthon L; Clarberg A; Davidsson P; Gottfries J; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Neurology; 1999 Oct; 53(7):1488-94. PubMed ID: 10534256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up.
    Blomberg M; Jensen M; Basun H; Lannfelt L; Wahlund LO
    Neurosci Lett; 1996 Aug; 214(2-3):163-6. PubMed ID: 8878109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
    Lasser RA; Dukoff R; Levy J; Levin R; Lehtimäki T; Seubert P; Sunderland T
    Int J Geriatr Psychiatry; 1998 Nov; 13(11):767-74. PubMed ID: 9850873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased CSF cortisol in AD is a function of APOE genotype.
    Peskind ER; Wilkinson CW; Petrie EC; Schellenberg GD; Raskind MA
    Neurology; 2001 Apr; 56(8):1094-8. PubMed ID: 11320185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease.
    Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Matsushita S; Machida N; Nakagawa T; Lee VM; Trojanowski JQ; Sasaki H
    J Am Geriatr Soc; 1997 Oct; 45(10):1228-31. PubMed ID: 9329486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
    Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
    Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.
    Itoh N; Arai H; Urakami K; Ishiguro K; Ohno H; Hampel H; Buerger K; Wiltfang J; Otto M; Kretzschmar H; Moeller HJ; Imagawa M; Kohno H; Nakashima K; Kuzuhara S; Sasaki H; Imahori K
    Ann Neurol; 2001 Aug; 50(2):150-6. PubMed ID: 11506396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.